Zoetis (ZTS) Q1 2026 Earnings Transcript

Zoetis reported Q1 revenue of $2.3 billion, up 3% reported but flat organically, while adjusted net income rose just 1%-2% amid weaker U.S. companion animal demand and intensifying competition. U.S. companion animal revenue fell 11% to $865 million, key dermatology declined 11% globally, and Librela dropped 13%, partially offset by 12% livestock growth and 10% diagnostics growth. Management lowered full-year guidance to $9.68 billion-$9.96 billion revenue and $2.87 billion-$2.95 billion adjusted net income, citing price sensitivity, lower clinic visits, and competitive pressure, while announcing an acquisition of Neogen's animal genomics business.

Analysis

The key issue is not a one-quarter miss; it is that Zoetis is discovering price elasticity in a category long presumed to be quasi-annuity-like. When clinic traffic weakens and distributors stop pre-buying, premium brands lose their usual insulation and promotional intensity becomes contagious — that dynamic can persist for several quarters because it is driven by channel economics, not just consumer mood. The second-order effect is that competitors with lower absolute dollar exposure and newer launches can spend more aggressively, extending the share grab window even if their products are less differentiated.

The U.S. companion animal reset is the real driver of multiple compression here: it pressures revenue, but more importantly it forces the market to reassess the durability of Zoetis’ pricing power and the timing of the next innovation cycle. A critical nuance is that the company is not defending share with broad price cuts; it is shifting toward point-of-sale affordability and channel access, which should preserve brand equity but likely slows near-term top-line recovery. That means the earnings bridge into 2H depends on stabilization in clinic visits and lapping softer channel inventory, not on a new demand inflection.

Contrarianly, the bearish case may be less severe than the headline implies. Livestock and diagnostics are acting as internal shock absorbers, and the companion animal weakness appears concentrated in developed markets where affordability pressure is most acute; emerging markets are still expanding. The market may be over-discounting a permanent structural decline when the more probable outcome is a 6–18 month digestion period, but the stock still needs time for evidence: sequential share stabilization, not just management commentary, before multiple re-rating becomes credible.

Key Decisions for Investors

• Short ZTS into any post-earnings bounce; prefer a 1-3 month horizon. Thesis: consensus is still underestimating how long channel destocking and competitive promo intensity can weigh on U.S. companion animal. Risk/reward improves if the stock re-rates on 'stabilization' language before hard data turns.
• Pair trade: long NEOG / short ZTS for 3-6 months. The Neogen genomics acquisition is a modest strategic positive for NEOG and a low-cost source of optionality for ZTS, but near term the market is rewarding diversification more than core growth quality; this pair isolates execution pressure at ZTS while keeping animal-health exposure.
• Buy ZTS put spreads 2-4 months out, struck around the pre-earnings implied move plus ~5-7%. This captures the risk that 2H guidance proves too dependent on easy comps and not enough on demand recovery. Define risk tightly because livestock strength can cushion downside.
• If you need to own animal health, rotate toward diagnostic supply-chain beneficiaries rather than end-market exposure. Look for names with levered benefit to reference lab and consumables growth, as those are less exposed to pet-owner affordability and clinic visit deferral.
• Monitor ZTS only for a long entry after two consecutive quarters of U.S. companion stabilization and retail replenishment reacceleration. Until then, the stock is a show-me story; any long should be sized as a tactical trade, not a core position.